Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Questions in the design of ANSWER

Trials including participants with advanced liver disease are challenging. In the open-label ANSWER trial, Paolo Caraceni and colleagues (May 31, p 2417)1 aimed to assess the effect of long-term albumin administration in decompensated cirrhosis on overall survival. The authors conclude that albumin administration is associated with improved overall survival. However, it is unclear whether this finding is robust.